# Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma

Source: https://onco.cc/trials/nct07324629/  
OnCo record `nct07324629` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Sacituzumab tirumotecan in thymoma and thymic carcinoma, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma is a phase 2 interventional study registered as NCT07324629 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 30 participants planned, started 2026-03-13 and due to reach its primary completion in 2028-04. Interventions recorded: Sacituzumab tirumotecan.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07324629
- Phase: 2
- Setting: A Phase II Clinical Study of Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma With Treatment Failure After Platinum-Based Therapy
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT07324629: https://clinicaltrials.gov/study/NCT07324629

## Connected records

- cancers: [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07324629.json